The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

Perrigo Rx Divestment Sees Firm Drop Out Of Top Five As Sun Rises

15 Aug 2022

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Generics Bulletin Top 50 2022 — A new order is emerging for the leading companies • Source: Shutterstock

In the ever-evolving global generics and biosimilars industry, one constant that can be relied upon is change. Even as the upheaval of the COVID-19 pandemic recedes, fresh political and economic pressures are being felt by firms across the world, while specific local trends are also playing their part in the fortunes of regional players.

Alongside these external factors, active strategic decisions made by the world’s off-patent industry leaders are also significantly reshaping the competitive landscape, transforming and reconfiguring some of the highest-profile companies in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vardenafil Leads UK Rises In January

14 Feb 2025

• By Dave Wallace

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.